Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers (2016)

  • Authors:
  • USP affiliated authors: TOZATTO, EDUARDO - FCFRP ; ANA, LAURO WICHERT - FMRP ; COELHO, EDUARDO BARBOSA - FMRP ; TAKAYANAGUI, OSVALDO MASSAITI - FMRP ; LANCHOTE, VERA LUCIA - FCFRP
  • USP Schools: FCFRP; FMRP; FMRP; FMRP; FCFRP
  • DOI: 10.1007/s00228-015-1970-4
  • Subjects: ANTICONVULSIVANTES; FARMACOCINÉTICA CLÍNICA; MOLÉCULA
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s00228-015-1970-4 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    Versões disponíveis em Acesso Aberto do: 10.1007/s00228-015-1970-4 (Fonte: Unpaywall API)

    Título do periódico: European Journal of Clinical Pharmacology

    ISSN: 0031-6970,1432-1041



      Não possui versão em Acesso aberto
    Informações sobre o Citescore
  • Título: European Journal of Clinical Pharmacology

    ISSN: 0031-6970

    Citescore - 2017: 2.69

    SJR - 2017: 1.159

    SNIP - 2017: 1.277


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FMRP2744887pcd 2744887 Estantes Deslizantes
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      ANTUNES, Natalícia de Jesus; WICHERT-ANA, Lauro; COELHO, Eduardo Barbosa; et al. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. European Journal of Clinical Pharmacology, Heidelberg, v. 72, n. 2, p. 195-201, 2016. Disponível em: < http://dx.doi.org/10.1007/s00228-015-1970-4 > DOI: 10.1007/s00228-015-1970-4.
    • APA

      Antunes, N. de J., Wichert-Ana, L., Coelho, E. B., Pasqua, O. D., Alexandre Junior, V., Takayanagui, O. M., et al. (2016). Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers. European Journal of Clinical Pharmacology, 72( 2), 195-201. doi:10.1007/s00228-015-1970-4
    • NLM

      Antunes N de J, Wichert-Ana L, Coelho EB, Pasqua OD, Alexandre Junior V, Takayanagui OM, Tozatto E, Marques MP, Lanchote VL. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers [Internet]. European Journal of Clinical Pharmacology. 2016 ; 72( 2): 195-201.Available from: http://dx.doi.org/10.1007/s00228-015-1970-4
    • Vancouver

      Antunes N de J, Wichert-Ana L, Coelho EB, Pasqua OD, Alexandre Junior V, Takayanagui OM, Tozatto E, Marques MP, Lanchote VL. Influence of verapamil on the pharmacokinetics of oxcarbazepine and of the enantiomers of its 10-hydroxy metabolite in healthy volunteers [Internet]. European Journal of Clinical Pharmacology. 2016 ; 72( 2): 195-201.Available from: http://dx.doi.org/10.1007/s00228-015-1970-4

    Referências citadas na obra
    Schimidt D, Sachdeot R (2000) Oxcarbazepine for treatment of partial epilepsy: a review and recommendations for clinical use. Epilepsy Behav 1:396–405
    Verrotti A, Coppola G, Parisi P, Mohn A, Chiarelli F (2010) Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 112:1–10
    Wellington K, Goa KL (2001) Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 15:137–163
    Flesch G, Francote E, Hell F, Degen PH (1992) Determination of the R-(−) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective high-performance liquid chromatography. J Chromatogr 581:147–151
    Malátková P, Havlíková L, Wsól V (2014) The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact 220:241–247
    Tecoma ES (1999) Oxcarbazepine. Epilepsia 40(Suppl 5):37–46
    Paglia G, D’apolito O, Garofalo D, Scarano C, Corso G (2007) Development and validation of a LC/MS/MS method for simultaneous quantification of oxcarbazepine and its main metabolites in human serum. J Chromatogr B 860:153–159
    Schütz H, Feldmann JF, Faigle JW (1986) The metabolism of 14C-oxcarbazepine in man. Xenobiotica 16:769–778
    Volosov A, Bialer M, Xiaodong S, Perucca E, Sintov A, Yagen B (2000) Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrodiol in human urine. J Chromatogr B 738:419–425
    Flesch G, Czendlik C, Renard D, Lloyd P (2011) Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. Drug Metab Dispos 39:1103–1110
    Patsalos PN, Elyas AA, Zakrzewska JM (1990) Protein binding of oxcarbazepine and its primary active metabolite, 10-hydroxycarbazepine, in patients with trigeminal neuralgia. Eur J Clin Pharmacol 39:413–415
    Bring P, Ensom HH (2008) Does oxcarbazepine warrant therapeutic drug monitoring? Clin Pharmacokinet 47(12):767–778
    Dickinson RG, Hooper WD, Dunstan PR, Eadie MJ (1989) First dose and steady-state pharmacokinetics of oxcarbazepine and its 10-hydroxy metabolite. Eur J Pharmacol 37:69–74
    Benet LZ (2009) Predicting drug disposition via application of a biopharmaceutics drug disposition classification system. Basic Clin Pharmacol Toxicol 106:162–167
    Aronica E, Sisodiya SM, Gorter JA (2012) Cerebral expression of drug transporters in epilepsy. Adv Drug Deliv Rev 64:919–929
    Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75(1):13–33
    Hillgren KM, Keppler D, Zur AA, Giacomini KM, Stieger B, Cass CE, Zhang L, International Transporter Consortium (2013) Emerging transporters of clinical importance: an update from the International Transporter Consortium. Clin Pharmacol Ther 94(1):52–63
    Kaur V, Garg T, Rath G, Goyal AK (2014) Therapeutic potential of nanocarrier for overcoming to P-glycoprotein. J Drug Target 7:1–12
    Estudante M, Marais JG, Soveral G, Benet LZ (2013) Intestinal drug transporters: an overview. Adv Drug Deliv Rev 65(10):1340–1356
    Zakeri-Milani P, Valizadeh H (2014) Intestinal transporters: enhanced absorption through P-glycoprotein-related drug interactions. Expert Opin Drug Metab Toxicol 10(6):859–871
    Amin ML (2013) P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27–34
    Varma MV, Ashokraj Y, Dey CS, Panchagnula R (2003) P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 48(4):347–359
    Wahajuddin RKS, Singh SP, Taneja I (2014) Investigation of the functional role of P-glycoprotein in limiting the oral bioavailability of lumefantrine. Antimicrob Agents Chemother 58(1):489–494
    Clinkers R, Smolders I, Meurs A, Ebinger G, Michotte Y (2005) Quantitative in vivo microdialysis study on the influence of multidrug transporters on the blood-brain barrier passage of oxcarbazepine: concomitant use of hippocampal monoaminases as pharmacodynamic markers for the anticonvulsant activity. J Pharmacol Exp Ther 314(2):725–731
    Lemma GL, Wang Z, Hamman MA, Zaheer NA, Gorski JC, Hall SD (2006) The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 79(3):218–230
    Antunes NJ, Wichert-Ana L, Coelho EB, Della Pasqua O, Alexandre Junior V, Takayanagui OM, Tozatto E, Lanchote VL (2013) Analysis of oxcarbazepine and the 10-hydroxycarbazepine enantiomers in plasma by LC-MS/MS : application in a pharmacokinetic study. Chirality 903:897–903
    Clinical Pharmacology & Therapeutics Editorial Team (2010) Statistical guide for clinical pharmacology & threrapeutics Clin Pharmacol Ther 88:150–152
    Dadashzadeha S, Javadiana B, Sadeghian S (2006) The effect of gender on the pharmacokinetics of verapamil and norverapamil in human. Biopharm Drug Dispos 27:329–334
    Nunes T, Rocha J, Falcão A, Almeida L, Soares-da-Silva P (2013) Steady-state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers. Epilepsia 54(1):108–116
    Grover A, Benet LZ (2009) Effects of drug transporters on volume of distribution. AAPS J 11(2):250–261